Review Article

Evaluation of Clinical Outcome after Laparoscopic Antireflux Surgery in Clinical Practice: Still a Controversial Issue

Sandro Contini1 and Carmelo Scarpignato2

1 Department of Surgical Sciences, University of Parma, 43125 Parma, Italy
2 Laboratory of Clinical Pharmacology, Division of Gastroenterology, Department of Clinical Sciences, School of Medicine & Dentistry, University of Parma, 43125 Parma, Italy

Correspondence should be addressed to Sandro Contini, sandro.contini@unipr.it

Received 16 April 2011; Accepted 28 June 2011

Academic Editor: Casey M. Calkins

Copyright © 2011 S. Contini and C. Scarpignato. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Laparoscopic antireflux surgery has shown to be effective in controlling gastroesophageal reflux (GERD). Yet, a universally accepted definition and evaluation for treatment success/failure in GERD is still controversial. The purpose of this paper is to assess if and how the outcome variables used in the different studies could possibly lead to an homogeneous appraisal of the limits and indications of LARS.

Methods. We analyzed papers focusing on the efficacy and outcome of LARS and published in English literature over the last 10 years.

Results. Symptoms scores and outcome variables reported are dissimilar and not uniform. The most consistent parameter was patient’s satisfaction (mean satisfaction rate: 88.9%). Antireflux medications are not a trustworthy outcome index. Endoscopy and esophageal manometry do not appear very helpful. Twenty-four hours pH metry is recommended in patients difficult to manage for recurrent typical symptoms.

Conclusions. More uniform symptoms scales and quality of life tools are needed for assessing the clinical outcome after laparoscopic antireflux surgery. In an era of cost containment, objective evaluation tests should be more specifically addressed. Relying on patient’s satisfaction may be ambiguous, yet from this study it can be considered a practical and simple tool.

1. Introduction

Laparoscopic antireflux surgery (LARS) has shown to be effective in controlling gastroesophageal reflux [1, 2]. However, a universally accepted definition for treatment success/failure in gastroesophageal reflux disease (GERD) is not yet available: objective evaluation of symptoms, response to treatment, and definition of treatment failure are all still controversial. A substantial number of the patients after surgery still take antireflux medications (ARMs) [3–5], with percentages ranging from 62% to 15–20% after 9 and 4-5 years of followup, respectively [6–12]. ARM use is performed on the assumption that foregut symptoms in a patient after fundoplication are consequent to a failed operation and based on the assumption that a diagnosis of recurrent reflux can be made confidently from the clinical findings [13, 14]. However, most patients taking acid suppressive medications after antireflux surgery do not reveal any abnormal esophageal acid exposure [15], and the presence of symptoms alone may not seem to be a good reason to start an antacid treatment. Therefore, the prescription of ARM frequently seems inappropriate and does not always indicate that surgical therapy has failed.

Reports dealing with the clinical outcome after LARS, either concentrate on symptomatic results, patient’s satisfaction, and quality of life, on the percentage of patients taking ARM, or on the objective evaluation of the esophageal function and acid exposure. Yet, there is not agreement on how should a successful outcome be defined and how could the consequent therapeutic approach be directed.

On this background, we felt worthwhile to analyze the recent literature, mainly focused on the efficacy and outcome of LARS. The purpose of this paper is therefore (i) to assess if and how the outcome variables used in the different studies could possibly lead, in spite of
their complexity, to an homogeneous appraisal of the limits and indications of LARS in the management of GERD,

(ii) how these outcome evaluations could be better interpreted in order to identify failures of treatment,

(iii) to possibly extrapolate and suggest a flowchart for the postoperative evaluation after LARS.

2. Methods

In order to evaluate criteria and definition of a successful clinical outcome after LARS, we analyzed studies, published after 2000, which were specifically performed to assess reflux symptoms, medication assumption, satisfaction to surgery, evaluation of quality of life, and objective esophageal tests after LARS. Specifically, for each study, it was taken into account:

(i) parameters utilized to assess the clinical outcome, that is, clinical evaluation or interview, phone interview, symptoms questionnaire or others (QoL, GIQLI, HRQL, GSRS, PGWB), analysis of hospital databases, level of satisfaction;

(ii) incidence of GERD and not GERD-related symptoms;

(iii) use of ARM (either continuous or occasional) for GERD-related and not GERD symptoms;

(iv) response to medications and, when specified, the main prescriber (family physician, gastroenterologist, surgeon);

(v) objective esophageal tests (endoscopy, esophageal manometry, 24-hour esophageal pH-metry) when performed.

3. Results

Thirty-four papers [2–6, 8, 11, 14–40] concerning clinical outcome after LARS were evaluated. The total number of patients included in this review was 7599, with a follow-up ranging from a minimum of 6 months to 12 years. The first author was a gastroenterologist in 7 (21.8%) papers and a surgeon in 26. Twenty-five studies came from highly specialized or university hospitals, 2 from VA cooperative studies [6, 26], 3 from cooperative studies between university hospitals [23, 36, 39], and 3 from community hospitals [3, 26, 28].

3.1. Clinical Assessment Tools. Different questionnaires were proposed to the patients in 23 studies, by clinical, phone, or postal interview, which are listed in Table 1. Patient’s appraisal was done by clinical evaluation during the follow-up visit in 7 studies, while one investigation was based on the review of VA clinical database of the outpatients clinics. Patients satisfaction was specifically investigated in 15 papers.

3.2. Satisfaction, Quality of Life, and Clinical Symptoms. The mean percentage of patients satisfied by surgery was high (88.9% ± 2.8%).

Ten studies assessed the quality of life after surgery, either comparing it to preoperative values or to a group of medically treated patients. The results are showed in Table 2. Quality of life scores improved after surgery but in only one study out of 4 the surgical group achieved a significantly better score than the medical group.

GERD symptoms scores showed an improvement after surgery in all series. However, GERD-related symptoms (heartburn and/or regurgitation) were still reported in 18.2 ± 12.3% of patients (range 4–47%) in 21 studies. Not GERD-related symptoms (including dysphagia, often a new symptom after surgery) were reported in 27.7 ± 18.8%, in 14 papers.

3.3. Antireflux Medications. ARMs for GERD-related symptoms after LARS are taken by 34.9% ± 15.9 of patients, in 21 (62.5%) studies (Table 3). Only 6 studies (18.7%) differentiated continuous from occasional treatment, and only 3 studies indicated the main prescriber (GP, gastroenterologist, surgeon, self-prescription). Moreover, only 5 studies indicated the rate of successful response to ARM for GERD-related symptoms (ranging from 25 to 95%), and only one gave details about the response to medical treatment for not GERD-related symptoms.

3.4. Endoscopy. The results of endoscopic examination as a part of the clinical assessment after surgery were reported in 8 studies (26.6%).

3.5. Esophageal Manometry. This test, specifically performed in 7 studies [8, 11, 15, 17, 19, 20, 38], showed a significant increase of lower esophageal sphincter (LES) pressure after surgery both in symptomatic and asymptomatic patients [19], usually at a short-term evaluation, with a drop in the long term in some studies [20] but not in others [11]. Some [15] did not observe any predictable change of esophageal peristalsis, while disordered esophageal motility was reported in 9% of the patients [19] (no mention of preoperative features). In one study [38] it has been found that patients with either a low or high postoperative LES pressure have a similar long-term symptoms profile with a significant linear correlation between difference in postoperative LES pressure and long-term symptom score for heartburn, dysphagia, and regurgitation. Finally, no correlation has been found between postoperative LES and symptoms or 24-hour pH recording [17].

3.6. 24 Hours Esophageal pH-metry. Patients were submitted to esophageal 24-hour pH-metry after LARS in 18 (54.5%) studies, with different indications and results (Table 4). The mean percentage of patients with abnormal score was 24% (range 16–62%), but the percentage of patients submitted to this test was very variable, ranging from 16 to 100%. The mean percentage of abnormal results among those taking ARM was 32% (Table 5).
Table 1: Parameters used for patients evaluation and number of studies.

| Parameters                              | Number of studies | Refs                                      |
|-----------------------------------------|-------------------|-------------------------------------------|
| Questionnaires                          |                   |                                           |
| GERD symptoms score                     | 23                | [3–6, 8, 11, 15, 16, 18, 20, 24, 25, 27, 29, 32–37, 39, 40] |
| Gastroesophageal Reflux Disease Activity Index (GRACY) |                   |                                           |
| Digestive Health Survey Instrument      |                   |                                           |
| Gastrointestinal Symptoms Rating Scale (GSRS) |                   |                                           |
| Jamieson Score                          |                   |                                           |
| Gastrointestinal Quality of Life Index (GIQLI) | 3                  | [25, 27, 33]                              |
| Psychological General Well-Being Index (PGWBI) | 2                  | [23, 39]                                  |
| Short-form 36 (SF 36)                   | 2                 | [6, 22]                                   |
| Health-Related Quality of Life (HRQL)   | 1                 | [34]                                      |
| Well-Being Score (WBS)                  | 1                 | [2]                                       |
| Visual Analogue Score (VAS)             | 1                 | [11]                                      |
| Patients satisfaction                   | 16                | [2–6, 11, 18, 20, 24, 29, 32–35, 38]      |
| VA clinical data base (outpatients clinics) | 1              | [26]                                      |
| Clinical assessment at follow-up visit  | 7                 | [4, 11, 19, 22, 31, 38, 39]              |
| Objective esophageal tests              |                   |                                           |
| Endoscopy                               | 8                 | [3, 6, 14, 15, 22, 23, 30, 31]            |
| Esophageal manometry                    | 7                 | [8, 11, 15, 17, 19, 20, 38]              |
| 24-h Esophageal pH-metry                | 18                | [6, 8, 11, 14–20, 27, 32–37, 40]         |

Table 2: HRQoL Assessment with different questionnaires and their results.

| Author                   | Year  | Ref. | Tools     | Results                                                                 |
|--------------------------|-------|------|-----------|-------------------------------------------------------------------------|
| Spechler et al.          | 2001  | [6]  | SF-36     | No significant difference between medical and surgical group            |
| Bammer et al.            | 2001  | [2]  | WBS       | Improved significantly at more than 5 years of followup                 |
| Olberg et al.            | 2005  | [23] | PGWBI     | No significant difference between medical and surgical group            |
| Contini and Scarpignato  | 2004  | [22] | SF-36     | Normal score 2 years after LARS                                         |
| Ciovica et al.           | 2006  | [27] | GIQLI + HRQL | QoL normalized after LARS and significantly higher than a medically treated group |
| Dallermagne et al.       | 2006  | [25] | GIQLI     | Significantly better than preoperatively at 10 years                    |
| Draaisma et al.          | 2006  | [11] | VAS       | 30% improvement after surgery                                           |
| Gee et al.               | 2008  | [34] | GERD−HRQL | Near normal score at long-term followup                                 |
| Fein et al.              | 2008  | [33] | GIQLI     | Significant improvement of the QoL after 10 years                       |
| Lundell et al.           | 2009  | [39] | PGWBI     | Similar to that of normal population in both surgical and medical group at 12 years |

VAS: Visual Analogue Scale.

4. Discussion

Laparoscopic antireflux surgery currently represents the golden standard in the surgical management of GERD, being a viable alternative to medical treatment, with minimal morbidity and mortality [8–10]. However, an accurate and universally accepted evaluation of the clinical outcome after LARS is still a critical issue. How to assess satisfaction and subjective symptoms of the patients, how and when to evaluate objectively the outcome in order to define an optimal response to surgery, and, finally, the connotation of a treatment failure, are still controversial topics. The surgical reports analyzed may be divided in 4 different groups:

(i) papers concentrated on perioperative morbidity and mortality or on technical problems, that is, type of fundoplication and their side effects and less deeply focused on a clear-cut long-term appraisal of the clinical outcome;
(ii) papers dealing with long-term symptomatic results, taking into account symptoms score, quality of life, and patient’s satisfaction;
(iii) papers highlighting the large number of patients taking ARM after LARS, generally prescribed on the base of the false assumption that foregut symptoms in a patient after fundoplication are consequent to a failed operation;
(iv) papers concentrated on the comparison of clinical outcome between medically and surgically treated patient population.
Clearly, this paper has inherent limits: the subjective choice of the reports to evaluate and the fact that it is neither a meta-analysis nor a systematic review of the whole literature. It mirrors, however, the current practice. Moreover, while most papers examined are coming from specialized and high-volume surgical centers for LARS, others report the result from community hospitals or from cooperative studies in hospitals at various levels of experience. It is well known that surgeon’s experience does matter and that surgeon’s experience does matter and that outcomes of laparoscopic fundoplication in routine clinical practice are poorer than those reported by referral centres. It was therefore not in the aims of this study to evaluate surgical results but rather to compare and highlight the difference/homogeneity of postoperative evaluations and to assess their clinical relevance.

4.1. Clinical Assessment. Only paper [8] specifically indicate a clinical interview as a part of the evaluation of postoperative symptoms. Most studies relied on mailed questionnaires or phone interview or even on the administrative and clinical database of outpatients clinics. Four different symptoms scores were used. All have been someway validated for clinical practice, but this disparity in the analysis tools certainly reveals a rather unstandardized approach to symptoms’ evaluation. Moreover, the way the information is collected as well as the completeness of the followup, sometimes very low, may influence the results and may account for some apparent differences in the clinical outcome, with a wide variation of the typical GERD-related symptoms (i.e., heartburn and/or regurgitation), ranging from 4.8 to 30% amongst the papers examined. Studies relying solely on mailed questionnaires may falsely elevate success rates, especially if followup is incomplete, and patients with worse outcomes may not be motivated to return the questionnaires [41]. In addition, outcomes reported at telephone interview may be more favorable, as well as there is a significant risk of bias in reporting of surgical outcomes when incomplete data are analyzed. The limitation inherent to outcome’s com-parison between different groups applying different data collection has already been outlined [41] and recently it has been strongly recommended the development of validated outcome instruments [42, 43].

The relevance of the presence of symptoms in the evaluation of clinical outcome may also be questioned, being often independent on an objective evidence of persistent GE reflux [44]. Symptomatic assessment has been shown to have low sensitivity and low positive predictive value for abnormal postoperative 24-hour pH-metry. Hence, it might be misleading to report a successful outcome after LARS, relying mainly on symptoms, whose sole presence is a poor indicator of recurrent reflux disease.

Assessment of quality of life has also been employed as outcome measure after antireflux surgery. In this study, we found that six different questionnaires were used to analyze the QoL, showing again a lack of homogeneity and standardization. In spite of this, results are consistent, and quality of life seems to improve uniformly after surgery in all reports, even in the long term, achieving the same scores observed in a normal sample population or in the group of medically treated patients. Although symptomatic (heartburn) patients, with or without a positive pH study, did not show any difference in the clinical outcome, with a wide variation of the symptoms, severe symptoms being usually associated to a significant decrease in patient’s satisfaction [32]. It is worthwhile mentioning that in a study [3], the satisfaction rate in patients without resolution of the symptoms was 69%. The use of ARMs does not influence significantly the satisfaction rate, thus suggesting that often the indications for these drugs are for vague and nonspecific symptoms, together with a low threshold by the patients for reinitiating medical treatment. In reality, a high proportion of patients, who complain moderate symptoms or side effects following surgery or who still require regular medication, are of the opinion that a fundoplication was to some extent advantageous. It comes out that relying on satisfaction only for a successful clinical outcome may be ambiguous and that it is needed a clear-cut definition or uniform score for satisfaction, a parameter

Table 3: Incidence of ARM use after LARS.

| Authors          | Year | Ref. | Followup (yrs) | Patients on ARM (%) |
|------------------|------|------|----------------|---------------------|
| Spechler et al.  | 2001 | [6]  | 6.4            | 23/37 (62%)         |
| Bammer et al.    | 2001 | [2]  | 6.4            | 24/171 (14%)        |
| Booth et al.     | 2002 | [18] | 2.0            | 19/140 (14%)        |
| Lord et al.      | 2002 | [14] | 2.4            | 37/86 (43%)         |
| Anvari and Allen | 2003 | [20] | 5.0            | 21/181 (12%)        |
| Bloomston et al. | 2003 | [5]  | 5.0            | 31/84 (37%)         |
| Papasavas et al. | 2003 | [8]  | 2.6            | 56/297 (19%)        |
| Vakil et al.     | 2003 | [3]  | 1.7            | 26/80 (33%)         |
| Velanovich et al.| 2003 | [21] | 2.4            | 16/122 (13%)        |
| Galvani et al.   | 2003 | [15] | 1.5            | 62/124 (50%)        |
| Contini and Scarpignato | 2004 | [22] | 2.0            | 13/50 (26%)         |
| Tucker et al.    | 2005 | [24] | 4.1            | 58/119 (49%)        |
| Thibault et al.  | 2006 | [28] | 3.6            | 38/121 (31%)        |
| Dominitz et al.  | 2006 | [26] | 4.5            | 1199/2406 (49.8%)   |
| Draaisma         | 2006 | [11] | 6.0            | 11/79 (13.9%)       |
| Bonatti et al.   | 2007 | [4]  | 2.4            | 37/94 (39%)         |
| Zaninotto et al. | 2007 | [31] | 8.0            | 30/145 (21%)        |
| Wijnhoven et al. | 2008 | [36] | 5.9            | 312/844 (37%)       |
| Oelschlager et al.| 2008 | [35] | 5.7            | 119/288 (41%)       |
| Thompson et al.  | 2009 | [40] | 4.6            | 42/69 (60.8%)       |
| Lundell et al.   | 2009 | [39] | 12             | 55/144 (38%)        |

Mean = 34.9%
### Table 4: Postoperative 24 hrs pH-metry. Indications and results.

| Authors          | Year | Ref. | Pts submitted to pH-metry (%) | Indications                          | Results                                      |
|------------------|------|------|-------------------------------|--------------------------------------|----------------------------------------------|
| Franzén et al.   | 1999 | [16] | 67/101 (66.3%)                | Follow-up                            | 19.4% abnormal score                         |
|                  |      |      |                               |                                      | No statistical difference between medical and surgical group. Small sample. Results inconclusive. |
| Spechler et al.  | 2001 | [6]  | 10/37 (27%)                  | Follow-up                            |                                              |
|                  |      |      |                               |                                      |                                              |
| Lord et al.      | 2002 | [14] | 86/86 (100%)                 | Follow-up, Symptomatic patients after LARS | 23% abnormal score                          |
| Arca et al.      | 2002 | [17] | 28/46 (49%)                  | Follow-up                            | 28% abnormal score                          |
| Booth et al.     | 2002 | [18] | 109/175 (78%)                | Follow-up                            | 5% abnormal score                           |
| Khajanchee et al.| 2002 | [19] | 209/209 (100%)              | Follow-up                            | 16.7% abnormal score                        |
| Galvani et al.   | 2003 | [15] | 124/124 (100%)              | Follow-up, Symptomatic patients after LARS | 39% abnormal score;                          |
| Gee et al.       | 2008 | [34] | 20/191 (10.4%)              | Follow-up (ARM)                       | 70% abnormal result                         |
| Anvari and Allen | 2003 | [20] | 181/332 (54.5%)             | Follow-up                            | Mean acid reflux score significantly lower than preop |
| Papasavas et al. | 2003 | [8]  | 93/297 (31.3%)              | Follow-up                            | Average percentage of exposed time <4 was significantly reduced |
| Ciovica et al.   | 2006 | [27] | 351/351 (100%)             | Follow-up                            | 10% Abnormal score                          |
| Draaisma et al.  | 2006 | [11] | ?/79                         | Follow-up                            | 12.5% Abnormal score                        |
| Morgenthal et al.| 2007 | [32] | 1/166                         | Follow-up                            | 14% abnormal score in pts on ARM (3/21)       |
| Oelschlager et al.| 2008| [35] | 58/288 (20.1%)              | Follow-up (heartburn)                | 22% abnormal result                         |
| Wijnhoven et al. | 2008 | [36] | 139/844 (16.4%)            | Follow-up Patients taking ARM after LARS | 22.3% abnormal results                      |
| Boddy et al.     | 2008 | [37] | 106/145 (73.1%)             | Follow-up (4 months)                 | No correlation between pH scores and symptoms score |
| Fein et al.      | 2008 | [33] | 67/99 (67.6%)               | Follow-up                            | 33% of pts with heartburn had recurrent reflux |
| Thompson et al.  | 2009 | [40] | 69/69 (100%)                | Follow-up, Symptomatic patients after LARS | 22% Abnormal score                          |

### Table 5: Abnormal esophageal exposure to acid in patients taking ARM after LARS.

| Authors            | Year | Ref. | Followup (months) | Pts with abnormal pH score (%) |
|--------------------|------|------|-------------------|-------------------------------|
| Booth et al.       | 2002 | [18] | 24                | 7/19 (36.8%)                 |
| Lord et al.        | 2002 | [14] | 27.8              | 9/37 (24.3%)                 |
| Galvani et al.     | 2003 | [15] | 17                | 48/124 (39.0%)               |
| Anvari and Allen   | 2003 | [20] | 60                | 9/21 (42.8%)                 |
| Draaisma et al.    | 2006 | [11] | 60                | Absence of correlation between the use of PPIs and documented reflux symptoms |
| Thompson et al.    | 2009 | [40] | 44                | 17/53 (32%)                  |
| Wijnhoven et al.   | 2008 | [36] | 70.8              | 16/61 (26.2%)                |
| Fein et al.        | 2008 | [33] | 24                | NA (42%)                     |
| Thompson et al.    | 2009 | [40] | 55                | 7/42 (16.6%)                 |
|                    |      |      |                   | Mean = 32.4%                  |
which may reward the surgeon but cannot probably be taken as a precise and reliable index of a successful LARS.

4.2. Antireflux Medications. One third of the patients is taking ARM after LARS in our review, but only 6 studies precise if the use of ARMs was regular or occasional [3, 4, 22, 23, 27, 36]. A recent meta-analysis of RCTs [45] found that—after antireflux surgery—14% of patients still require ARMs. This figure increases with the duration of followup, and up to one third of patients required acid-lowering drugs after 10 years. The data from nonrandomized studies [46], which are higher than data from randomized studies (i.e., 20% of patients under ARMs), are probably more representative of the current clinical practice.

Some authors consider medication use as an outcome measure for successful antireflux surgery [6], while others suggest that use of ARM does not correlate with true recurrent reflux in the majority of the patients [18, 20, 32] and does not necessarily indicate a failure of the procedure. A significant proportion of patients taking medications after operation are using them to relieve nonreflux-related symptoms, and only one third of patients of them showed an abnormal exposure to acid (Table 5). In one study, 79% of patients on ARM took drugs for abdominal or chest symptoms thought to be unrelated to reflux, often pre-existing to surgery [2]. Many of these patients may restart medications on their own or have them prescribed empirically without proven needs. An analysis of an administrative database, likely addressed to expert providers, highlights the likelihood of continued anti-reflux medications after surgery in up to 50% of patients [26]. Therefore, not only the high postoperative use of ARM is questionable and often incorrect, but also it may not be a reliable and trustworthy tool for the evaluation of surgical outcome.

4.3. Objective Evaluation of the Esophagus. In general, objective outcome measures, probably the better way to evaluate the outcome, are not used frequently, especially in the long-term followup, due to the difficulty of the patients to accept uncomfortable procedures, and this consequently brings a less complete followup. Usually, postoperative objective testing is recommended in presence of persistent or recurrent symptoms after LARS and not in asymptomatic patients, which is realistic in an era of cost containment. However, this approach may not be appropriate, since many symptomatic patients do not show any pathologic reflux at 24-hour pH-metry; conversely, asymptomatic patient may have significant pathological reflux [19].

4.4. Endoscopy. Upper GI endoscopy was carried out in a low percentage of patient’s population and failed to provide any useful critical information. Relationship with symptoms was poor, and the evaluation and grading of esophageal lesions (when present) were found to be extremely subjective. As a consequence, “standard” endoscopic examination is unlikely to influence postoperative management.

4.5. Esophageal Manometry. While a significant postoperative increase of LES pressure has been found in successful, asymptomatic patients [47], other investigations failed to show any significant difference in pressure increase between symptomatic and asymptomatic patients [48]. Moreover, no correlation has been found between postoperative LES pressure and symptoms or 24 hour pH-metry results [17]. Taking into account the inconsistent manometric findings and the difficult acceptance of the procedure by the patients, it is hard to propose it as a regular and trustable postoperative test, its role being secondary to esophageal pH recording in symptomatic patients.

4.6. 24 Hour Esophageal pH-metry. In the papers examined, postoperative 24-hour pH-metry has been the most frequently performed objective test, mainly to identify patients with true recurrent gastroesophageal reflux. The reproducibility of 24-hour pH monitoring is essential to make it reliable. Actually, a concordance rate of 96% in repeated test was recently reported [40]. Ideally, patients with recurring symptoms should undergo a 24-hour pH probe study for an objective evaluation and quantitation of acidic reflux. We do not feel that such test should be recommended postoperatively on a routine basis. Indeed, finding a positive test in an asymptomatic patient would be challenging due to the lack of established guidelines in this clinical setting. On the other hand, successful operations, as demonstrated by a normal exposure to acid, may not eliminate all reflux-related symptoms. Although nonacid reflux could be responsible for symptoms, it has been shown to be very uncommon [49]. Moreover, a recent investigation [50] reported that persistent symptoms are neither caused by acid nor by weakly acidic reflux, but rather by abnormal air handling. To investigate weakly acidic or nonacidic reflux-related symptoms, a combined pH-impedance study is needed, but this test is more costly and technically demanding.

5. Conclusions

The evaluation of efficacy of LARS as a permanent treatment for GERD definitely depends on determining what should be considered a successful outcome. This study highlights the need to be careful when considering clinical outcomes reported after antireflux surgery. The complexity in capturing data is evident. Not only symptoms assessment may be considered not appropriate in some studies, but also symptoms scores and outcome variables reported in different studies are dissimilar, making a plea for more uniform symptoms scales and quality of life tools. This would be of utmost importance in the clinical practice, where either gastroenterologists or primary care physicians need to understand that most patients complaining of postoperative symptoms do not have pathologic reflux.

Relying on patient’s satisfaction to define a successful surgical outcome may be ambiguous and cannot probably be taken as a precise and reliable index of a successful procedure, yet from this study it can be considered a practical and simple tool, with uniform results.
References

[1] D. I. Watson, G. G. Jamieson, P. G. Devitt et al., “A prospective randomized trial of laparoscopic Nissen fundoplication with anterior vs posterior hiatal repair,” *Archives of Surgery*, vol. 136, no. 7, pp. 745–751, 2001.

[2] T. Bammer, R. A. Hinder, A. Klaus, and P. J. Klingler, “Five-to eight-year outcome of the first laparoscopic Nissen fundoplications,” *Journal of Gastrointestinal Surgery*, vol. 5, no. 1, pp. 42–48, 2001.

[3] N. Vakil, M. Shaw, and R. Kirby, “Clinical effectiveness of laparoscopic fundoplication in a U.S. community,” *American Journal of Medicine*, vol. 114, no. 1, pp. 1–5, 2003.

[4] H. Bonatti, T. Bammer, S. R. Achem et al., “Use of acid suppressive medications after laparoscopic antireflux surgery: prevalence and clinical indications,” *Digestive Diseases and Sciences*, vol. 52, no. 1, pp. 267–272, 2007.

[5] M. Bloomston, W. Nielsd, and A. S. Rosemurgy, “Symptoms and antireflux medication use following laparoscopic Nissen fundoplication: outcome at 1 and 4 years,” *Journal of the Society of Laparoendoscopic Surgeons*, vol. 7, no. 3, pp. 211–218, 2003.

[6] S. J. Spechler, E. Lee, D. Ahnen et al., “Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial,” *Journal of the American Medical Association*, vol. 285, no. 18, pp. 2331–2338, 2001.

[7] S. Rice, D. I. Watson, C. J. Lally, P. G. Devitt, P. A. Game, and G. G. Jamieson, “Laparoscopic anterior 180 degrees partial fundoplication: five-year results and beyond,” *Archives of Surgery*, vol. 141, no. 3, pp. 271–275, 2006.

[8] P. K. Papasavas, R. J. Keenan, W. Y. Yeany, P. F. Caushaj, D. J. Gagné, and R. J. Landreneau, “Effectiveness of laparoscopic fundoplication in relieving the symptoms of gastroesophageal reflux disease (GERD) and eliminating antireflux medical therapy,” *Surgical Endoscopy*, vol. 17, no. 8, pp. 1200–1205, 2003.

[9] L. Lundell, P. Miettinen, H. E. Myrvold et al., “Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease,” *Journal of the American College of Surgeons*, vol. 192, no. 2, pp. 172–181, 2001.

[10] T. Lafullarde, D. I. Watson, G. G. Jamieson, J. C. Myers, P. A. Game, and P. G. Devitt, “Laparoscopic Nissen fundoplication: five-year results and beyond,” *Archives of Surgery*, vol. 136, no. 2, pp. 180–184, 2001.

[11] W. A. Draaisma, H. G. Rijnhart-de Jong, I. A. M. Broeders, A. J. P. M. Smout, E. J. B. Furnee, and H. G. Gooszen, “Five-year subjective and objective results of laparoscopic and conventional Nissen fundoplication: a randomized trial,” *Annals of Surgery*, vol. 244, no. 1, pp. 34–41, 2006.

[12] M. B. Fennerty, D. Castell, A. M. Fendrick et al., “The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: suggested disease management guidelines,” *Archives of Internal Medicine*, vol. 156, no. 5, pp. 477–484, 1996.

[13] A. Sonnenberg, F. Delcò, and H. B. El-Serag, “Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis,” *Digestive Diseases and Sciences*, vol. 43, no. 5, pp. 1001–1008, 1998.

[14] R. V. N. Lord, A. Kaminski, S. Öberg et al., “Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after nissen fundoplication,” *Journal of Gastrointestinal Surgery*, vol. 6, no. 1, pp. 3–10, 2002.

[15] C. Galvani, P. M. Fischella, M. V. Gorodner et al., “Symptoms are a poor indicator of reflux status after fundoplication for gastroesophageal reflux disease: role of esophageal functions tests,” *Archives of Surgery*, vol. 138, no. 5, pp. 514–519, 2003.

[16] T. Franzén, J. Boström, L. T. Grahn, and K. E. Johansson, “Prospective study of symptoms and gastro-oesophageal reflux 10 years after posterior partial fundoplication,” *British Journal of Surgery*, vol. 86, no. 7, pp. 956–960, 1999.

[17] M. J. Arca, M. Gagner, A. García-Ruiz, and B. T. Heniford, “The significance of pH and manometric testing after laparoscopic fundoplication: are postoperative physiologic tests necessary?” *Surgical Endoscopy*, vol. 16, no. 3, pp. 395–400, 2002.

[18] M. I. Booth, L. Jones, J. Stratford, and T. C. B. Dehn, “Results of laparoscopic Nissen fundoplication at 2–8 years after surgery,” *British Journal of Surgery*, vol. 89, no. 4, pp. 476–481, 2002.

[19] Y. S. Khajanee, R. W. O’Rourke, B. Lockhart et al., “Postoperative symptoms and failure after antireflux surgery,” *Archives of Surgery*, vol. 137, no. 9, pp. 1008–1014, 2002.

[20] M. Anvari and C. Allen, “Five-year comprehensive outcomes evaluation in 181 patients after laparoscopic Nissen fundoplication,” *Journal of the American College of Surgeons*, vol. 196, no. 1, pp. 51–59, 2003.

[21] V. Velanovich, “Medication usage and additional esophageal procedures after antireflux surgery,” *Surgical Laparoscopy, Endoscopy and Percutaneous Techniques*, vol. 13, no. 3, pp. 161–164, 2003.

[22] S. Contini and C. Scarpignato, “Does the learning phase influence the late outcome of patients with gastroesophageal reflux disease after laparoscopic fundoplication?” *Surgical Endoscopy*, vol. 18, no. 2, pp. 266–271, 2004.

[23] P. Olberg, R. Johannessen, G. Johnsen et al., “Long-term outcome of surgically and medically treated patients with gastroesophageal reflux disease: a matched-pair follow-up study,” *Scandinavian Journal of Gastroenterology*, vol. 40, no. 3, pp. 264–274, 2005.

[24] F. E. Tucker, C. Blatt, N. L. Richardson, D. T. Richardson, J. D. Cassat, and T. B. Riechers, “Laparoscopic nissen fundoplication in a community hospital: patient satisfaction survey,” *Southern Medical Journal*, vol. 98, no. 4, pp. 441–443, 2005.

[25] B. Dallemagne, J. Weerts, S. Markiewicz et al., “Clinical results of laparoscopic fundoplication at ten years after surgery,” *Surgical Endoscopy*, vol. 20, no. 1, pp. 159–165, 2006.

[26] J. A. Dominitz, C. A. Dire, K. G. Billingsley, and J. A. Todd-Stenberg, “Complications and antireflux medication use after antireflux surgery,” *Clinical Gastroenterology and Hepatology*, vol. 4, no. 3, pp. 299–305, 2006.

[27] R. Giovica, M. Gadenstätter, A. Klingler, W. Lechner, O. Riedl, and G. P. Schwab, “Quality of life in GERD patients: medical treatment versus antireflux surgery,” *Journal of Gastrointestinal Surgery*, vol. 10, no. 7, pp. 934–939, 2006.

[28] R. Thibault, E. Coron, V. Sibille et al., “Antireflux surgery for non-erosive and erosive reflux disease in community practice,” *Alimentary Pharmacology and Therapeutics*, vol. 24, no. 4, pp. 621–632, 2006.

[29] A. Madan and A. Minocha, “Despite high satisfaction, majority of gastro-oesophageal reflux disease patients continue to use proton pump inhibitors after antireflux surgery,” *Alimentary Pharmacology and Therapeutics*, vol. 23, no. 5, pp. 601–605, 2006.

[30] L. Lundell, P. Miettinen, H. E. Myrvold et al., “Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophageitis,” *British Journal of Surgery*, vol. 94, no. 2, pp. 198–203, 2007.
[31] S. A. Antoniou, G. Portale, M. Costantini et al., “Long-term results (6–10 years) of laparoscopic fundoplication,” *Journal of Gastrointestinal Surgery*, vol. 11, no. 9, pp. 1138–1145, 2007.

[32] C. B. Morgenthal, M. D. Shane, A. Stival et al., “The durability of Laparoscopic Nissen fundoplication: 11-year outcomes,” *Journal of Gastrointestinal Surgery*, vol. 11, no. 6, pp. 693–700, 2007.

[33] M. Fein, M. Bueter, A. Thalheimer et al., “Ten-year outcome of laparoscopic antireflux surgery,” *Journal of Gastrointestinal Surgery*, vol. 12, no. 11, pp. 1893–1899, 2008.

[34] D. W. Gee, M. T. Andreoli, and D. W. Rattner, “Measuring the effectiveness of laparoscopic antireflux surgery: long-term results,” *Archives of Surgery*, vol. 143, no. 5, pp. 482–487, 2008.

[35] B. K. Oelschlager, E. Quiroga, J. D. Parra, M. Cahill, N. Polisar, and C. A. Pellegrini, “Long-term outcomes after laparoscopic antireflux surgery,” *American Journal of Gastroenterology*, vol. 103, no. 2, pp. 280–287, 2008.

[36] B. P. L. Wijnhoven, C. J. Lally, J. J. Kelly, J. C. Myers, and D. I. Watson, “Use of antireflux medication after antireflux surgery,” *Journal of Gastrointestinal Surgery*, vol. 12, no. 3, pp. 510–517, 2008.

[37] A. P. Boddy, S. Mehta, J. Bennett, R. Lowndes, D. Mahon, and M. Rhodes, “Postoperative esophageal physiology studies may help to predict long-term symptoms following laparoscopic Nissen fundoplication,” *Surgical Endoscopy*, vol. 22, no. 5, pp. 1298–1302, 2008.

[38] S. A. Antoniou, P. Delivoria, G. A. Antoniou et al., “Symptom-focused results after laparoscopic fundoplication for refractory gastroesophageal reflux disease—a prospective study,” *Langenbeck’s Archives of Surgery*, vol. 393, no. 6, pp. 979–984, 2008.

[39] L. Lundell, P. Miettinen, H. E. Myrvold et al., “Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis,” *Clinical Gastroenterology and Hepatology*, vol. 7, no. 12, pp. 1292–1298, 2009.

[40] S. K. Thompson, W. Cai, G. G. Jamieson et al., “Recurrent symptoms after fundoplication with a negative pH study-recurrent reflux or functional heartburn?” *Journal of Gastrointestinal Surgery*, vol. 13, no. 1, pp. 54–60, 2009.

[41] R. Ludemann, D. I. Watson, and G. G. Jamieson, “Influence of follow-up methodology and completeness on apparent clinical outcome of fundoplication,” *American Journal of Surgery*, vol. 186, no. 2, pp. 143–147, 2003.

[42] Y. Yuan and R. H. Hunt, “Evolving issues in the management of reflux disease?” *Current Opinion in Gastroenterology*, vol. 25, no. 4, pp. 342–351, 2009.

[43] J. Dent, P. J. Kahrlas, N. Vakil et al., “Clinical trial design in adult reflux disease: a methodological workshop,” *Alimentary Pharmacology and Therapeutics*, vol. 28, no. 1, pp. 107–126, 2008.

[44] A. D. Jenkins, S. S. Kadirkamanathan, S. M. Scott, E. Yazaki, and D. F. Evans, “Relationship between symptom response and oesophageal acid exposure after medical and surgical treatment for gastro-oesophageal reflux disease,” *British Journal of Surgery*, vol. 91, no. 11, pp. 1460–1465, 2004.

[45] Y. Yuan, N. D. Dattani, C. Scarpignato, and R. H. Hunt, “Use of antisecretory medication after antireflux surgery for patients with gastroesophageal reflux disease (GERD): a systematic review of randomized control trials (RCTs),” *The American Journal of Gastroenterology*, vol. 104, supplement 3, p. S25, 2009.

[46] Y. Yuan, N. Dattani, C. Scarpignato, and R. H. Hunt, “Use of antisecretory medication (ARM) after antireflux surgery (ARS) for patients with gastroesophageal reflux disease (GERD): a systematic review of non-randomized studies,” *Gut*, vol. 59, no. 4, supplement 1, pp. A116–A117, 2010.